krsnaa is looking good now
If there is a slight bounce from 600, it looks like it could go to 650 to 690.
If it breaks the major level of 600, then it seems that it can go up to 530 comfortably
A major fib level of 726 is coming which after breaking it can start an uptrend (which doesn't seem to break in this scenario.)
We have tried to give some view on this...
Chembio Diagnostics' analysts are forecasting revenues of US$54m in 2021, a substantial 56% improvement in sales compared to the last year.
CEMI follows its bigger more profitable brother CODX in price action.
Depending on the future development of the global pandemic, those stocks could grow rapidly.
On 12/3/2020 Craig Hallum brokerage Upgraded the stock from...
LSE:ODX A friend of mine asked me to look into ODX, I made this for him and thought I could share with a wider public.
As a disclaimer, I'm still not a big expert of Eliott waves, so I'd be happy to hear any constructive feedback.
Entry. $0.69
S/L $0.60
TP $0.92
12 months Consensus Price Target: $3
if you find my charts useful, please leave me "like" or "comment".
Please don't trade according to the ideas, rely on your own knowledge.
Thx
For the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above.
While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself...
Last week, ENZO BIOCHEM INC - NYSE:ENZ broke to higher ground and in the process, recaptured its 200 DMA out of a rounding bottom and now finds itself digesting/consolidating the move within a Flag pattern on lower volume as is evidenced in the Daily chart above.
In addition, ENZ is now trading above all of its important moving averages 20/50/200 DMA's and...
Photocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks.
As mentioned in an earlier TradingView analysis ( ), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time.
Entry at...
Blood diagnostic OncoCEE-BR was used by Columbia University College of Physicians and Surgeons in New York City to aid cancer patients' diagnosis. Involved biopsies are no longer required, cancer can be detected with a simple blood test. The chart has strong bullish divergence, has just made a breakout with an initial target around 4 dollars.
